(Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma
Status:
Recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
Phase 2 open-label single arm intervention study administering encorafenib/binimetinib in
neo-adjuvant setting followed by surgery and subsequent adjuvant encorafenib/binimetinib in
in-transit melanoma patients without lymph node and distant metastases.